Bioluminescence-based high-throughput screen identifies pharmacological agents that target neurotransmitter signaling in small cell lung carcinoma

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Improgo, Ma Reina D ^a   Johnson, Christopher W ^a   Tapper, Andrew R ^a   Gardner, Paul D ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CORTEXOLONE MALEATE; CORTODOXONE; FLUOXETINE; LUCIFERASE; LUCIFERIN; STAUROSPORINE AGLYCONE; STAUROSPORINE DERIVATIVE; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTINEOPLASTIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; SEROTONIN RECEPTOR AFFECTING AGENT; STAUROSPORINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CELL ASSAY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MARKER; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LUNG SMALL CELL CANCER; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PROCESS DEVELOPMENT; RNA INTERFERENCE; SEROTONINERGIC TRANSMISSION; SIGNAL TRANSDUCTION; ANIMAL; CELL STRAIN HEK293; CELL SURVIVAL; DOSE RESPONSE; GENETICS; LUMINESCENCE; LUNG TUMOR; METABOLISM; METHODOLOGY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (PHOSPHORYLATING); HEK293 CELLS; HUMANS; LUCIFERASES; LUMINESCENT MEASUREMENTS; LUNG NEOPLASMS; MICE; NEUROTRANSMITTER AGENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SEROTONIN AGENTS; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA; STAUROSPORINE; TIME FACTORS;

EID: 80052526127     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024132     Document Type: Article

References (29)

1. WHO (2011) Cancer Fact Sheet World Health Organization.
2. ACS (2009) Cancer Statistics 2009 American Cancer Society.
3. Junker K, Wiethege T, Muller KM, (2000) Pathology of small-cell lung cancer. J Cancer Res Clin Oncol 126: 361-368.
4. Sandler AB, (2003) Chemotherapy for small cell lung cancer. Semin Oncol 30: 9-25.
5. Govindan R, Page N, Morgensztern D, Read W, Tierney R, et al. (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24: 4539-4544.
6. Hynes J, Floyd S, Soini AE, O'Connor R, Papkovsky DB, (2003) Fluorescence-based cell viability screening assays using water-soluble oxygen probes. J Biomol Screen 8: 264-272.
7. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
8. Fan F, Wood KV, (2007) Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol 5: 127-136.
9. DeLuca M, McElroy WD, (1974) Kinetics of the firefly luciferase catalyzed reactions. Biochemistry 13: 921-925.
10. NRC (1996) Guide for the care and use of laboratory animals.
11. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
12. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, et al. (2007) High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 3: 466-479.
13. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
14. Pettengill OS, Sorenson GD, Wurster-Hill DH, Curphey TJ, Noll WW, et al. (1980) Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung. Cancer 45: 906-918.
15. Nakanishi S, Matsuda Y, Iwahashi K, Kase H, (1986) K-252b, c and d, potent inhibitors of protein kinase C from microbial origin. J Antibiot (Tokyo) 39: 1066-1071.
16. Rosenberg B, (1979) Anticancer activity of cis-dichlorodiammineplatinum(II) and some relevant chemistry. Cancer Treat Rep 63: 1433-1438.
17. Vila MR, Nicolas A, Morote J, de I, Meseguer A, (2000) Increased glyceraldehyde-3-phosphate dehydrogenase expression in renal cell carcinoma identified by RNA-based, arbitrarily primed polymerase chain reaction. Cancer 89: 152-164.
18. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
19. Onganer PU, Seckl MJ, Djamgoz MB, (2005) Neuronal characteristics of small-cell lung cancer. Br J Cancer 93: 1197-1201.
20. Schuller HM, (2008) Neurotransmission and cancer: implications for prevention and therapy. Anticancer Drugs 19: 655-671.
21. Hunter T, (2009) Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol 21: 140-146.
22. Julien SG, Dube N, Hardy S, Tremblay ML, (2011) Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 11: 35-49.
23. Heasley LE, (2001) Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 20: 1563-1569.
24. Senogles SE, (2007) D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69. Anticancer Drugs 18: 801-807.
25. Ishibashi M, Fujisawa M, Furue H, Maeda Y, Fukayama M, et al. (1994) Inhibition of growth of human small cell lung cancer by bromocriptine. Cancer Res 54: 3442-3446.
26. Cattaneo MG, Palazzi E, Bondiolotti G, Vicentini LM, (1994) 5-HT1D receptor type is involved in stimulation of cell proliferation by serotonin in human small cell lung carcinoma. Eur J Pharmacol 268: 425-430.
27. Cattaneo MG, Fesce R, Vicentini LM, (1995) Mitogenic effect of serotonin in human small cell lung carcinoma cells via both 5-HT1A and 5-HT1D receptors. Eur J Pharmacol 291: 209-211.
28. Jull BA, Plummer HK 3rd, Schuller HM, (2001) Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. J Cancer Res Clin Oncol 127: 707-717.
29. Mailman RB, Murthy V, (2010) Ligand functional selectivity advances our understanding of drug mechanisms and drug discovery. Neuropsychopharmacology 35: 345-346.